{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:37:36Z","timestamp":1789133856946,"version":"build-2803163510"},"reference-count":138,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System (2023\u20132025)","award":["GWVI-11.2-XD04"],"award-info":[{"award-number":["GWVI-11.2-XD04"]}]},{"name":"Three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System (2023\u20132025)","award":["GWVI-11.1-01"],"award-info":[{"award-number":["GWVI-11.1-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Group A Streptococcus (GAS) imposes a significant global health burden across all age groups, annually causing over 600 million cases of pharyngitis and more than 18 million severe invasive infections or sequelae. The resurgence of scarlet fever globally and streptococcal toxic shock syndrome (STSS) outbreaks in Japan have brought GAS infections back into the spotlight as a pressing global health concern. Unfortunately, no licensed vaccine against GAS is yet available for clinical use. Our comprehensive review examines the developmental history of GAS vaccines, outlining the research trajectory from early inactivated vaccines to contemporary multivalent, conjugate, multi-antigen, and mRNA-based vaccine platforms. It systematically analyzes clinical trial outcomes of GAS vaccines, highlighting recent advances in both M protein-based and non-M protein vaccine candidates while summarizing promising target antigens. The review concludes with critical strategies to accelerate vaccine commercialization, including enhanced investment in research and development, expanded collaborations, leveraging advanced vaccine technologies, streamlined clinical trials, and strengthened public health advocacy. This review critically evaluates the current evidence and future prospects in GAS vaccine development, emphasizing innovative strategies and engaging broader stakeholders to accelerate GAS vaccine development.<\/jats:p>","DOI":"10.3390\/vaccines13070734","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T10:03:27Z","timestamp":1751882607000},"page":"734","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Engaging Broader Stakeholders to Accelerate Group A Streptococcus Vaccine Development"],"prefix":"10.3390","volume":"13","author":[{"given":"Dechuan","family":"Kong","sequence":"first","affiliation":[{"name":"Department of Communicable Diseases Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Communicable Diseases Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Office of the Director, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Communicable Diseases Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1473-3099(18)30231-7","article-title":"Resurgence of scarlet fever in China: A 13-year population-based surveillance study","volume":"18","author":"Liu","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S1473-3099(17)30693-X","article-title":"Resurgence of scarlet fever in England, 2014\u20132016: A population-based surveillance study","volume":"18","author":"Lamagni","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Keuleyan, E., Todorov, T., Donchev, D., Kevorkyan, A., Vazharova, R., Kukov, A., Todorov, G., Georgieva, B., Altankova, I., and Uzunova, Y. (2025). Characterization of Streptococcus pyogenes Strains from Tonsillopharyngitis and Scarlet Fever Resurgence, 2023-FIRST Detection of M1UK in Bulgaria. Microorganisms, 13.","DOI":"10.3390\/microorganisms13010179"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101449","DOI":"10.1016\/j.nmni.2024.101449","article-title":"Emergence of STSS in Japan: An assessment of the threat and containment strategies","volume":"60\u201361","author":"Choudhary","year":"2024","journal-title":"New Microbes New Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3201\/eid3104.241076","article-title":"Emerging Trends in Streptococcal Toxic Shock Syndrome, Japan","volume":"31","author":"Ujiie","year":"2025","journal-title":"Emerg. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jama.2025.0910","article-title":"Invasive Group A Streptococcal Infections in 10 US States","volume":"333","author":"Gregory","year":"2025","journal-title":"JAMA"},{"key":"ref_7","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Lond. Engl., 396, 1204\u20131222."},{"key":"ref_8","unstructured":"GBD 2021 Diseases and Injuries Collaborators (2024). Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet Lond. Engl., 403, 2133\u20132161."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0012-3692(15)50887-8","article-title":"Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU","volume":"130","author":"Mehta","year":"2006","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/cid\/ciab597","article-title":"Health-Economic Value of Vaccination Against Group A Streptococcus in the United States","volume":"74","author":"Andrejko","year":"2022","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Johnson, A.F., and LaRock, C.N. (2021). Antibiotic Treatment, Mechanisms for Failure, and Adjunctive Therapies for Infections by Group A Streptococcus. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.760255"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/ijmm.IJMM_18_107","article-title":"Trends in Antimicrobial Resistance Patterns of Group A Streptococci, Molecular Basis and Implications","volume":"36","author":"Abraham","year":"2018","journal-title":"Indian J. Med. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3855\/jidc.9132","article-title":"Molecular epidemiology of macrolide resistant Group A streptococci from Puducherry, India","volume":"11","author":"Abraham","year":"2017","journal-title":"J. Infect. Dev. Ctries"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1128\/AAC.46.12.3987-3990.2002","article-title":"Erythromycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in Italy","volume":"46","author":"Dicuonzo","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1099\/jmm.0.023317-0","article-title":"emm typing, antibiotic resistance and PFGE analysis of Streptococcus pyogenes in Lebanon","volume":"60","author":"Bahnan","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jac\/dki286","article-title":"Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004","volume":"56","author":"Tamayo","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lapthorne, S., McWade, R., Scanlon, N., N\u00ed Bhaoill, S., Page, A., O\u2019Donnell, C., Dornikova, G., Hannan, M., Lynch, B., and Lynch, M. (2024). Rising clindamycin resistance in group A Streptococcus in an Irish healthcare institution. Access. Microbiol., 6.","DOI":"10.1099\/acmi.0.000772.v4"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.49.5.2109-2111.2005","article-title":"Rapid Inversion of the Prevalences of Macrolide Resistance Phenotypes Paralleled by a Diversification of T and emm Types among Streptococcus pyogenes in Portugal","volume":"49","author":"Ramirez","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jama.1930.02710380010003","article-title":"The biologic products of streptococcus cardioarthritidis: Therapeutic and prophylactic value in rheumatic disease in children","volume":"94","author":"Wilson","year":"1930","journal-title":"J. Am. Med. Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(00)97333-1","article-title":"Intravenous vaccines of h\u00e6molytic streptococci in acute rheumatism in childhood","volume":"220","author":"Collis","year":"1932","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.48.6.751","article-title":"Variants of hemolytic streptococci; their relation to type-specific substance, virulence, and toxin","volume":"48","author":"Todd","year":"1928","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4049\/jimmunol.89.3.307","article-title":"Current Knowledge of Type-Specific M Antigens of Group A Streptococci1","volume":"89","author":"Lancefield","year":"1962","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1128\/CMR.2.3.285","article-title":"Streptococcal M protein: Molecular design and biological behavior","volume":"2","author":"Fischetti","year":"1989","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/0264-410X(96)00050-3","article-title":"Recombinant, octavalent group A streptococcal M protein vaccine","volume":"14","author":"Dale","year":"1996","journal-title":"Vaccine"},{"key":"ref_26","first-page":"2188","article-title":"Recombinant tetravalent group A streptococcal M protein vaccine","volume":"151","author":"Dale","year":"1993","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_27","first-page":"833","article-title":"Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes","volume":"12","author":"Dale","year":"2005","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.vaccine.2019.12.005","article-title":"Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study","volume":"38","author":"Pastural","year":"2020","journal-title":"Vaccine."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1073\/pnas.071559398","article-title":"Complete genome sequence of an M1 strain of Streptococcus pyogenes","volume":"98","author":"Ferretti","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0264-410X(98)00150-9","article-title":"Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments","volume":"17","author":"Dale","year":"1999","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/erv.09.33","article-title":"Moving forward: A mucosal vaccine against group A streptococcus","volume":"8","author":"Georgousakis","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1073\/pnas.0406641102","article-title":"Extracellular deoxyribonuclease made by group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response","volume":"102","author":"Sumby","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"126205","DOI":"10.1016\/j.vaccine.2024.126205","article-title":"Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine","volume":"42","author":"Finn","year":"2024","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ics.2005.12.002","article-title":"A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults","volume":"1289","author":"McNeil","year":"2006","journal-title":"Int. Congr. Ser."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/374800","article-title":"Protection against group A streptococcus by immunization with J8-diphtheria toxoid: Contribution of J8- and diphtheria toxoid-specific antibodies to protection","volume":"187","author":"Batzloff","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1038\/s41467-020-17299-x","article-title":"Cross-serotype protection against group A Streptococcal infections induced by immunization with SPy_2191","volume":"11","author":"Sanduja","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jinf.2016.02.002","article-title":"Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG","volume":"72","author":"Reglinski","year":"2016","journal-title":"J. Infect."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.292.6.709","article-title":"Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: Phase 1 trial","volume":"292","author":"Kotloff","year":"2004","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1086\/444458","article-title":"Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers","volume":"41","author":"McNeil","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/intimm\/9.11.1723","article-title":"Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus","volume":"9","author":"Hayman","year":"1997","journal-title":"Int. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.vaccine.2013.02.013","article-title":"Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS)","volume":"31","author":"Hartas","year":"2013","journal-title":"Vaccine"},{"key":"ref_42","first-page":"2692","article-title":"Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help","volume":"190","author":"Pandey","year":"2013","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sekuloski, S., Batzloff, M.R., Griffin, P., Parsonage, W., Elliott, S., Hartas, J., O\u2019Rourke, P., Marquart, L., Pandey, M., and Rubin, F.A. (2018). Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198658"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zaman, M., Abdel-Aal, A.B., Fujita, Y., Phillipps, K.S., Batzloff, M.R., Good, M.F., and Toth, I. (2012). Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: Structure-activity relationship. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030146"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/505146","article-title":"Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization","volume":"194","author":"Batzloff","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1016\/j.vaccine.2007.01.079","article-title":"Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles","volume":"25","author":"Shaila","year":"2007","journal-title":"Vaccine"},{"key":"ref_47","unstructured":"University of Alberta (2025, April 29). A Randomized Double Blinded Within Dose, Controlled, Safety and Immunogenicity Study of GAS Vaccine Candidate in Healthy Individuals. clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04882514."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1186\/s13063-024-08634-4","article-title":"A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers","volume":"25","author":"Hawkes","year":"2024","journal-title":"Trials"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2567.1996.d01-754.x","article-title":"Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci","volume":"89","author":"Brandt","year":"1996","journal-title":"Immunology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0264-410X(97)00178-3","article-title":"Human antibodies to the conserved region of the M protein: Opsonization of heterologous strains of group A streptococci","volume":"15","author":"Brandt","year":"1997","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/intimm\/11.4.569","article-title":"Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities","volume":"11","author":"Brandt","year":"1999","journal-title":"Int. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1567201811310010007","article-title":"M-protein-derived conformational peptide epitope vaccine candidate against Group A Streptococcus","volume":"10","author":"Skwarczynski","year":"2013","journal-title":"Curr. Drug Deliv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0928-8244(04)00003-3","article-title":"Immune response to superoxide dismutase in group A streptococcal infection","volume":"40","author":"McMillan","year":"2004","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1128\/IAI.72.12.7342-7345.2004","article-title":"Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model","volume":"72","author":"McArthur","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_55","first-page":"115","article-title":"Immune responses of a liposome\/ISCOM vaccine adjuvant against streptococcal fibronectin binding protein 1 (Sfb1) in mice","volume":"119","author":"McArthur","year":"2024","journal-title":"Indian J. Med. Res"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3201\/eid0503.990310","article-title":"Adhesins as targets for vaccine development","volume":"5","author":"Wizemann","year":"1999","journal-title":"Emerg. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"An, Y.H., and Friedman, R.J. (2000). Handbook of Bacterial Adhesion: Principles, Methods, and Applications, Humana Press.","DOI":"10.1007\/978-1-59259-224-1"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Loh, J.M.S., Rivera-Hernandez, T., McGregor, R., Khemlani, A.H.J., Tay, M.L., Cork, A.J., MRaynes, J., Moreland, N.J., Walker, M.J., and Proft, T. (2021). A multivalent T-antigen-based vaccine for Group A Streptococcus. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-83673-4"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Loh, J.M.S., Lorenz, N., Tsai, C.J., Khemlani, A.H.J., and Proft, T. (2017). Mucosal vaccination with pili from Group A Streptococcus expressed on Lactococcus lactis generates protective immune responses. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-07602-0"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/imcb.12643","article-title":"Expanding strain coverage of a group A Streptococcus pilus-expressing Lactococcus lactis mucosal vaccine","volume":"101","author":"Pilapitiya","year":"2023","journal-title":"Immunol. Cell Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0165-5876(02)00021-6","article-title":"Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice","volume":"63","author":"Yokoyama","year":"2002","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.chom.2014.05.009","article-title":"The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design","volume":"15","author":"Cole","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/498618","article-title":"Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection","volume":"193","author":"Sabharwal","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1021\/acsinfecdis.0c00722","article-title":"Immunogenicity Assessment of Cell Wall Carbohydrates of Group A Streptococcus via Self-Adjuvanted Glyco-lipopeptides","volume":"7","author":"Khatun","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Fan, X., Wang, X., Li, N., Cui, H., Hou, B., Gao, B., Cleary, P.P., and Wang, B. (2014). Sortase A induces Th17-mediated and antibody-independent immunity to heterologous serotypes of group A streptococci. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107638"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wang, G., Zhao, J., Zhao, Y., Wang, S., Feng, S., and Gu, G. (2021). Immunogenicity Assessment of Different Segments and Domains of Group a Streptococcal C5a Peptidase and Their Application Potential as Carrier Protein for Glycoconjugate Vaccine Development. Vaccines, 9.","DOI":"10.3390\/vaccines9020139"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1086\/377700","article-title":"Immune response to group A streptococcal C5a peptidase in children: Implications for vaccine development","volume":"188","author":"Shet","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00693-19","DOI":"10.1128\/mBio.00693-19","article-title":"An Experimental Group A Streptococcus Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model","volume":"10","author":"Carnathan","year":"2019","journal-title":"mBio."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1128\/IAI.73.12.7878-7886.2005","article-title":"Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils","volume":"73","author":"Park","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e00618-16","DOI":"10.1128\/mBio.00618-16","article-title":"Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models","volume":"7","author":"Pandey","year":"2016","journal-title":"mBio"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Herrera, A.L., Van Hove, C., Hanson, M., Dale, J.B., Tweten, R.K., Huber, V.C., Diel, D., and Chaussee, M.S. (2020). Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0235139"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"24111","DOI":"10.1021\/acsomega.1c07360","article-title":"Non-Native Amino Acid Click Chemistry-Based Technology for Site-Specific Polysaccharide Conjugation to a Bacterial Protein Serving as Both Carrier and Vaccine Antigen","volume":"7","author":"Kapoor","year":"2022","journal-title":"ACS Omega"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Troese, M.J., Burlet, E., Cunningham, M.W., Alvarez, K., Bentley, R., Thomas, N., Carwell, S., and Morefield, G.L. (2023). Group A Streptococcus Vaccine Targeting the Erythrogenic Toxins SpeA and SpeB Is Safe and Immunogenic in Rabbits and Does Not Induce Antibodies Associated with Autoimmunity. Vaccines, 11.","DOI":"10.3390\/vaccines11091504"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1208\/s12248-017-0069-5","article-title":"Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes","volume":"19","author":"Burlet","year":"2017","journal-title":"AAPS J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1016\/j.vaccine.2014.04.092","article-title":"Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes","volume":"32","author":"Morefield","year":"2014","journal-title":"Vaccine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e00509-13","DOI":"10.1128\/mBio.00509-13","article-title":"Structure-informed design of an enzymatically inactive vaccine component for group A Streptococcus","volume":"4","author":"Henningham","year":"2013","journal-title":"mBio"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acsinfecdis.0c00047","article-title":"Development of an Enzyme-Mediated, Site-Specific Method to Conjugate Toll-Like Receptor 2 Agonists onto Protein Antigens: Toward a Broadly Protective, Four Component, Group A Streptococcal Self-Adjuvanting Lipoprotein-Fusion Combination Vaccine","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1107\/S1744309113024871","article-title":"Cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of SpyCEP, a candidate antigen for a vaccine against Streptococcus pyogenes","volume":"69","author":"Abate","year":"2013","journal-title":"Acta Crystallograph. Sect. F Struct. Biol. Cryst. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00109-012-0897-9","article-title":"Conserved anchorless surface proteins as group A streptococcal vaccine candidates","volume":"90","author":"Henningham","year":"2012","journal-title":"J. Mol. Med. Berl. Ger."},{"key":"ref_80","first-page":"176","article-title":"The economic and health burdens of diseases caused by group A Streptococcus in New Zealand","volume":"103","author":"Cannon","year":"2021","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41541-023-00659-1","article-title":"Global economic burden per episode for multiple diseases caused by group A Streptococcus","volume":"8","author":"Lee","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1016\/j.vaccine.2018.10.001","article-title":"An economic case for a vaccine to prevent group A streptococcus skin infections","volume":"36","author":"Cannon","year":"2018","journal-title":"Vaccine."},{"key":"ref_83","unstructured":"(2025, May 20). WHO Preferred Product Characteristics for Group A Streptococcus Vaccines. Available online: https:\/\/www.who.int\/publications\/i\/item\/who-preferred-product-characteristics-for-group-a-streptococcus-vaccines."},{"key":"ref_84","unstructured":"(2025, April 27). Search for: Other Terms: \u201cGroup A Streptococcus\u201d AND \u201cVaccine\u201d|List Expert Search|ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/expert-search?term=%22Group%20A%20Streptococcus%22%20AND%20%22vaccine%22."},{"key":"ref_85","unstructured":"(2025, April 27). Search for: Other Terms: Dengue Vaccine|List Expert Search|ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/expert-search?term=Dengue%20Vaccine."},{"key":"ref_86","unstructured":"(2025, April 27). Search for: Other Terms: HIV Vaccine|List Expert Search|ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/expert-search?term=HIV%20vaccine."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41541-023-00646-6","article-title":"Optimal global spending for group A Streptococcus vaccine research and development","volume":"8","author":"Tortorice","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_88","unstructured":"(2025, April 27). SAVAC Web. Available online: https:\/\/savac.ivi.int\/."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/CMR.00024-15","article-title":"Pneumococcal Capsules and Their Types: Past, Present, and Future","volume":"28","author":"Geno","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1017\/cts.2023.537","article-title":"Recent innovations in adaptive trial designs: A review of design opportunities in translational research","volume":"7","author":"Kaizer","year":"2023","journal-title":"J. Clin. Transl. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"106225","DOI":"10.1016\/j.cct.2020.106225","article-title":"Innovative trial designs and analyses for vaccine clinical development","volume":"100","author":"Liu","year":"2021","journal-title":"Contemp. Clin. Trials."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/2168479016666587","article-title":"FDA\u2019s Expedited Programs and Their Impact on the Availability of New Therapies","volume":"51","author":"Damle","year":"2017","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Wong, J.C., Lao, C.T., Yousif, M.M., and Luga, J.M. (2022). Fast Tracking-Vaccine Safety, Efficacy, and Lessons Learned: A Narrative Review. Vaccines, 10.","DOI":"10.3390\/vaccines10081256"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Dada, S., McKay, G., Mateus, A., and Lees, S. (2019). Lessons learned from engaging communities for Ebola vaccine trials in Sierra Leone: Reciprocity, relatability, relationships and respect (the four R\u2019s). BMC Public Health, 19.","DOI":"10.1186\/s12889-019-7978-4"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJMp2027405","article-title":"Developing Safe and Effective COVID Vaccines\u2014Operation Warp Speed\u2019s Strategy and Approach","volume":"383","author":"Slaoui","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJMp2026393","article-title":"Evaluating and Deploying COVID-19 Vaccines\u2014The Importance of Transparency, Scientific Integrity, and Public Trust","volume":"383","author":"Schwartz","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/d41586-020-03626-1","article-title":"The lightning-fast quest for COVID vaccines\u2014And what it means for other diseases","volume":"589","author":"Ball","year":"2021","journal-title":"Nature"},{"key":"ref_99","unstructured":"CDC (2025, April 28). How Influenza (Flu) Vaccines Are Made. Influenza (Flu). 30 September 2024, Available online: https:\/\/www.cdc.gov\/flu\/vaccine-process\/index.html."},{"key":"ref_100","first-page":"73","article-title":"Improving HPV Vaccination Uptake Among Adolescents in Low Resource Settings: Sociocultural and Socioeconomic Barriers and Facilitators","volume":"15","author":"Xu","year":"2024","journal-title":"Adolesc. Health Med. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/jan.16653","article-title":"HPV Vaccine Hesitancy and Uptake: A Conceptual Analysis Using Rodgers\u2019 Evolutionary Approach","volume":"81","author":"Kyei","year":"2025","journal-title":"J. Adv. Nurs."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Santangelo, O.E., Provenzano, S., Di Martino, G., and Ferrara, P. (2024). COVID-19 Vaccination and Public Health: Addressing Global, Regional, and Within-Country Inequalities. Vaccines, 12.","DOI":"10.3390\/vaccines12080885"},{"key":"ref_103","unstructured":"(2025, April 28). Vaccine Equity. Available online: https:\/\/www.who.int\/campaigns\/vaccine-equity."},{"key":"ref_104","unstructured":"(2025, April 28). Vaccine Inequity Undermining Global Economic Recovery. Available online: https:\/\/www.who.int\/news\/item\/22-07-2021-vaccine-inequity-undermining-global-economic-recovery."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Macr\u00ec, S., Spinello, C., Widomska, J., Magliozzi, R., Poelmans, G., Invernizzi, R.W., Creti, R., Roessner, V., Bartolini, E., and Margarit, I. (2018). Neonatal corticosterone mitigates autoimmune neuropsychiatric disorders associated with streptococcus in mice. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-28372-3"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e164762","DOI":"10.1172\/jci.insight.164762","article-title":"Dopamine receptor autoantibody signaling in infectious sequelae differentiates movement versus neuropsychiatric disorders","volume":"9","author":"Menendez","year":"2024","journal-title":"JCI Insight"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.autrev.2015.04.005","article-title":"Post-infectious group A streptococcal autoimmune syndromes and the heart","volume":"14","author":"Martin","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.mp.4001542","article-title":"PANDAS: Current status and directions for research","volume":"9","author":"Snider","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Putra, T.M.H., Rodriguez-Fernandez, R., Widodo, W.A., Elfiana, M., Laksono, S., Nguyen, Q.N., Tan, J.W.C., and Narula, J. (2023). Myocardial fibrosis in rheumatic heart disease: Emerging concepts and clinical implications. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1230894"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"eadd9232","DOI":"10.1126\/sciimmunol.add9232","article-title":"Group A Streptococcus induces CD1a-autoreactive T cells and promotes psoriatic inflammation","volume":"8","author":"Chen","year":"2023","journal-title":"Sci. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.3201\/eid2910.230675","article-title":"Expansion of Invasive Group A Streptococcus M1UK Lineage in Active Bacterial Core Surveillance, United States, 2019\u20132021","volume":"29","author":"Li","year":"2023","journal-title":"Emerg. Infect. Dis."},{"key":"ref_112","first-page":"2300422","article-title":"Increase in bloodstream infections caused by emm1 group A Streptococcus correlates with emergence of toxigenic M1UK, Belgium, May 2022 to August 2023","volume":"28","author":"Lin","year":"2023","journal-title":"Euro Surveill. Bull. Eur. Sur. Mal. Transm. Eur. Commun. Dis. Bull."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1038\/s41467-024-47929-7","article-title":"Rapid expansion and international spread of M1UK in the post-pandemic UK upsurge of Streptococcus pyogenes","volume":"15","author":"Vieira","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3201\/eid2905.221887","article-title":"Emerging Invasive Group A Streptococcus M1UK Lineage Detected by Allele-Specific PCR, England, 20201","volume":"29","author":"Zhi","year":"2023","journal-title":"Emerg. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41579-023-00865-7","article-title":"Pathogenesis, epidemiology and control of Group A Streptococcus infection","volume":"21","author":"Brouwer","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"8156","DOI":"10.1016\/j.vaccine.2011.07.142","article-title":"Improving reverse vaccinology with a machine learning approach","volume":"29","author":"Bowman","year":"2011","journal-title":"Vaccine"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Teahan, B., Ong, E., and Yang, Z. (2021). Identification of Mycobacterium tuberculosis Antigens with Vaccine Potential Using a Machine Learning-Based Reverse Vaccinology Approach. Vaccines, 9.","DOI":"10.3390\/vaccines9101098"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"W671","DOI":"10.1093\/nar\/gkab279","article-title":"Vaxign2: The second generation of the first Web-based vaccine design program using reverse vaccinology and machine learning","volume":"49","author":"Ong","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e25797","DOI":"10.1002\/jia2.25797","article-title":"Structure-guided envelope trimer design in HIV-1 vaccine development: A narrative review","volume":"24","author":"Derking","year":"2021","journal-title":"J. Int. AIDS Soc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41467-025-56114-3","article-title":"A single residue switch mediates the broad neutralization of Rotaviruses","volume":"16","author":"Huang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e2961","DOI":"10.1002\/jmr.2961","article-title":"Computational design of immunogenic peptide constructs comprising multiple human leukocyte antigen restricted dengue virus envelope epitopes","volume":"35","author":"Kaushal","year":"2022","journal-title":"J. Mol. Recognit. JMR"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"104646","DOI":"10.1016\/j.micpath.2020.104646","article-title":"Engineering an efficient poly-epitope vaccine against Toxoplasma gondii infection: A computational vaccinology study","volume":"152","author":"Forouharmehr","year":"2021","journal-title":"Microb. Pathog."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coviro.2015.03.013","article-title":"Computational tools for epitope vaccine design and evaluation","volume":"11","author":"He","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.06.053","article-title":"Nasal vaccination with poly(\u03b2-amino ester)-poly(d,l-lactide-co-glycolide) hybrid nanoparticles","volume":"529","author":"Sinani","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.biomaterials.2015.10.034","article-title":"Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands","volume":"75","author":"Pavot","year":"2016","journal-title":"Biomaterials"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1021\/acs.bioconjchem.7b00738","article-title":"Targeted Strategies for Mucosal Vaccination","volume":"29","author":"Longet","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2017.03.397","article-title":"BCG vaccine powder-laden and dissolvable microneedle arrays for lesion-free vaccination","volume":"255","author":"Chen","year":"2017","journal-title":"J. Control Release Off. J. Control Release Soc."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1700164","DOI":"10.1002\/smll.201700164","article-title":"Dissolving Microneedle Arrays for Transdermal Delivery of Amphiphilic Vaccines","volume":"13","author":"An","year":"2017","journal-title":"Small Weinh. Bergstr. Ger."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41564-020-00815-6","article-title":"A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model","volume":"6","author":"Hawman","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.7150\/thno.23438","article-title":"Efficient delivery of nucleic acid molecules into skin by combined use of microneedle roller and flexible interdigitated electroporation array","volume":"8","author":"Huang","year":"2018","journal-title":"Theranostics"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.adn4955","article-title":"A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection","volume":"386","author":"Alameh","year":"2024","journal-title":"Science"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Igy\u00e1rt\u00f3, B.Z., and Qin, Z. (2024). The mRNA-LNP vaccines\u2014The good, the bad and the ugly?. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1336906"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Blakney, A.K., Ip, S., and Geall, A.J. (2021). An Update on Self-Amplifying mRNA Vaccine Development. Vaccines, 9.","DOI":"10.3390\/vaccines9020097"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1016\/j.vaccine.2013.07.049","article-title":"A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/cmi.2008.11","article-title":"Salmonella typhi: From a human pathogen to a vaccine vector","volume":"5","author":"Zhang","year":"2008","journal-title":"Cell. Mol. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/JVI.02308-14","article-title":"Rhabdovirus-based vaccine platforms against henipaviruses","volume":"89","author":"Kurup","year":"2015","journal-title":"J. Virol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.coviro.2020.09.003","article-title":"Rhabdoviruses as vectors for vaccines and therapeutics","volume":"44","author":"Scher","year":"2020","journal-title":"Curr. Opin. Virol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/7\/734\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:05:58Z","timestamp":1760033158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/7\/734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":138,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["vaccines13070734"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13070734","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}